Sealed Air agrees to $10.3B all-cash acquisition by CD&R, offering $42.15 per share—a 41% premium. Company begins 30-day go-shop period for alternative bids.
Repare Therapeutics agrees to be acquired by XenoTherapeutics, offering shareholders cash, CVRs, and future milestone potential as the deal targets an early 2026 closing.